Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105

Hematol Oncol. 2022 Nov 23. doi: 10.1002/hon.3103. Online ahead of print.
No abstract available

Publication types

  • Letter